AstraZeneca and Daiichi Sankyo’s Enhertu has been approved in China by China’s National Medical Products Administration, or NMPA, as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens, the company announced. Enhertu is a specifically engineered HER2-directed antibody drug conjugate being jointly developed and commercialised by AstraZeneca and Daiichi Sankyo.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AZN:
- AstraZeneca announces license agreement with KYM Biosciences for CMG901
- AstraZeneca reports Imfinzi plus Imjudo approved in EU for NSCLC
- AstraZeneca says Calquence tablet formulation approved in EU for CLL
- AstraZeneca price target raised to 11,900 GBp from 10,100 GBp at UBS
- AstraZeneca, Merck present final results from Phase III PROpel trial